Monopar Therapeutics (MNPR)
59.42
0.00 (0.00%)
Upcoming Events
Latest Headlines
H.C. Wainwright Reiterates Buy Rating on Monopar Therapeutics (MNPR)
June 2, 2026 6:58 AM - StreetInsider
Monopar presents Phase 2 data showing ALXN1840 benefits for Wilson disease
June 1, 2026 7:00 AM - StreetInsider
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
June 1, 2026 7:00 AM - StreetInsider
Form 8-K Monopar Therapeutics For: May 29
May 29, 2026 4:57 PM - SEC Filing
Monopar study shows ALXN1840 improves copper balance in Wilson disease
May 19, 2026 5:33 PM - StreetInsider
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
May 19, 2026 5:33 PM - StreetInsider
Form 8-K Monopar Therapeutics For: May 19
May 19, 2026 5:27 PM - SEC Filing
Form SCHEDULE 13G Monopar Therapeutics Filed by: Saturn V Capital Management LP
May 15, 2026 1:26 PM - SEC Filing
Monopar Therapeutics (MNPR) Misses Q1 EPS by 46c
May 15, 2026 6:12 AM - StreetInsider
Form 10-Q Monopar Therapeutics For: Mar 31
May 14, 2026 2:01 PM - SEC Filing
Form 8-K Monopar Therapeutics For: May 14
May 14, 2026 2:00 PM - SEC Filing
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 14, 2026 2:00 PM - Globe NewsWire
Form SCHEDULE 13G/A Monopar Therapeutics Filed by: Adage Capital Management, L.P.
May 13, 2026 9:11 AM - SEC Filing
Form ARS Monopar Therapeutics For: Dec 31
April 30, 2026 4:26 PM - SEC Filing
Form DEFA14A Monopar Therapeutics
April 30, 2026 4:26 PM - SEC Filing
Form DEF 14A Monopar Therapeutics For: Jun 22
April 30, 2026 4:02 PM - SEC Filing
Lake Street on Monopar Therapeutics (MNPR): attractive risk/reward entry point
April 21, 2026 8:52 AM - StreetInsider
BTIG Reaffirms Buy Rating for Monopar Therapeutics (MNPR) Following Strong Phase 3 Wilson Disease Data
April 20, 2026 2:59 PM - StreetInsider
Form 8-K Monopar Therapeutics For: Apr 19
April 20, 2026 6:22 AM - SEC Filing
Monopar presents positive Phase 3 data for Wilson disease treatment
April 19, 2026 7:00 PM - StreetInsider
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
April 19, 2026 7:00 PM - StreetInsider
Jones Trading Assumes Monopar Therapeutics (MNPR) at Buy
April 6, 2026 4:16 PM - StreetInsider
Form 4 Monopar Therapeutics For: Mar 31 Filed by: Robinson Chandler
April 2, 2026 3:04 PM - SEC Filing
Form 4 Monopar Therapeutics For: Mar 31 Filed by: Cittadine Andrew
April 2, 2026 3:03 PM - SEC Filing
Form 10-K/A Monopar Therapeutics For: Dec 31
April 1, 2026 12:25 PM - SEC Filing
BTIG Reiterates Buy Rating on Monopar Therapeutics (MNPR)
March 30, 2026 5:08 AM - StreetInsider
Leerink Partners on Monopar Therapeutics (MNPR): shares don't reflect 'magnitude of market opportunity'
March 27, 2026 4:37 PM - StreetInsider
Raymond James Reiterates Outperform Rating on Monopar Therapeutics (MNPR) following Q4 results
March 27, 2026 4:30 PM - StreetInsider
Form 8-K Monopar Therapeutics For: Mar 27
March 27, 2026 1:28 PM - SEC Filing
Form 10-K Monopar Therapeutics For: Dec 31
March 27, 2026 1:01 PM - SEC Filing
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
March 27, 2026 1:00 PM - StreetInsider
Full Article List
